InsidersTradesSigma
Track the Establishment Labs Holdings INC. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Establishment Labs Holdings INC. has published 179 reports. Market capitalisation: €2.8bn. The latest transaction was filed on 10 July 2026 (Attribution). Among the most active insiders: LEWIN NICHOLAS SHERIDAN. All data is free.
179
Insider Decl.
n/a
Thresholds
€5m
18 ops.
Buy Volume
€20m
28 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Establishment Labs Holdings INC. Strong Buy (bullish), based on 9 analysts. Average price target: US$95.33.
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,877 of 29,064 companies
29.1
score / 100
Value27
Quality31
FCF yld-2.8%
Earn yld-2.5%
EV/EBITDA·
ROE-175%
Gross mgn69%
Net mgn-24%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 July 2026
Declarations179 total
11,315 shares0Common SharesSEC:0001742429-26-000022:0
239 sharesCommon SharesSEC:0001863404-26-000005:0
25,320 shares@ US$74.390.076% mcap10.4% of flowCommon SharesSEC:0001104659-26-067739:0
113 shares@ US$72.500.0003% mcap0.0% of flowCommon SharesSEC:0001104659-26-067739:1
65,100 shares@ US$72.890.19% mcap26.2% of flowCommon SharesSEC:0001104659-26-067739:2
3,580 shares@ US$70.560.010% mcap1.4% of flowCommon SharesSEC:0001104659-26-065826:0
16,999 shares@ US$71.400.049% mcap6.7% of flowCommon SharesSEC:0001104659-26-065826:1
4,936 shares@ US$64.8340.012% mcap5.7% of flowCommon SharesSEC:0001742429-26-000015:0
30,549 shares@ US$65.330.073% mcap35.5% of flowCommon SharesSEC:0001742429-26-000015:1
6,757 shares@ US$66.2040.016% mcap8.0% of flowCommon SharesSEC:0001742429-26-000015:2
400 shares@ US$67.3570.0010% mcap0.5% of flowCommon SharesSEC:0001742429-26-000015:3
22,610 shares@ US$65.6570.054% mcap26.4% of flowCommon SharesSEC:0001742429-26-000015:4
7,568 shares@ US$66.1290.018% mcap8.9% of flowCommon SharesSEC:0001742429-26-000015:5
1,007 shares@ US$65.9070.0024% mcap1.2% of flowCommon SharesSEC:0001742429-26-000015:6
1,008 shares@ US$66.460.0024% mcap1.2% of flowCommon SharesSEC:0001742429-26-000015:7
165 shares@ US$67.1440.0004% mcap0.2% of flowCommon SharesSEC:0001742429-26-000015:8
37,500 shares@ US$65.2280.088% mcap30.1% of flowCommon SharesSEC:0001742429-26-000011:0
14,266 shares0Common SharesSEC:0001839059-26-000003:0
36,780 sharesCommon SharesSEC:0001254555-26-000003:0
363 shares@ US$56.7812.5% of flowCommon SharesSEC:0001863404-26-000002:0
330 shares@ US$56.783.5% of flowCommon SharesSEC:0001254555-26-000002:0
440 shares@ US$56.780.5% of flowCommon SharesSEC:0001398327-26-000002:0
286 shares@ US$56.789.9% of flowCommon SharesSEC:0001861660-26-000002:0
297 shares@ US$56.784.1% of flowCommon SharesSEC:0001862601-26-000002:0
3,575 shares@ US$60.0752.6% of flowCommon SharesSEC:0001742429-26-000009:0
25 of 179 declarations
关于 Establishment Labs Holdings INC.
Establishment Labs Holdings Inc. 是一家在美国纳斯达克（美国）上市的医疗技术公司。该公司专注于女性健康和福祉，核心专长是乳房美学和重建。其商业模式围绕用于隆胸、乳房重建和相关微创美容手术的医疗设备的设计、制造和商业化。实际上，ESTA 不是一家多元化的医疗技术集团；它是一家专注于临床差异化和外科医生采纳的专业公司，采用高端品牌战略。 该公司由 Juan José Chacón-Quirós 创立，并围绕 Motiva® 平台建立了其市场形象，该平台已成为其旗舰产品系列。Motiva 植入物及相关技术是该公司的主要商业产品，并得到不断扩大的创新管线的支持，其中包括微创产品和更广泛的女性美容解决方案。Establishment Labs 将自己定位为一家全球医疗技术公司，致力于通过科学、工程和技术改善女性健康和福祉。 从地理上看，该公司拥有广泛的国际足迹。其 2025 年年度报告显示，在美国、几个欧洲国家、巴西和阿根廷设有子公司和运营实体，反映出其多区域的商业和分销网络。管理层还表示，Motiva 设备已在超过 85 个国家/地区上市，这突显了该公司已建立的国际影响力。这种全球影响力在竞争中很重要，因为乳房植入物市场受到高度监管并由品牌主导：成功取决于监管批准、外科医生信任、上市后声誉和持续的产品性能。 近期一个重要的里程碑是 Motiva 植入物于 2024 年获得美国 FDA 批准，随后在美国商业上市。该批准具有战略意义，因为美国是全球最大、最有价值的美容外科市场之一。2025 年和 2026 年初的最新公司更新显示，美国 Motiva 销售额不断增长，毛利率提高，运营亏损明显减少，这表明美国市场的推出正开始实现有意义的规模化。该公司最新业绩还强调了收入增长和调整后 EBITDA 的改善，这进一步强化了 ESTA 正在从国际利基市场参与者转变为更成熟的商业增长故事的观点。对于投资者而言，Establishment Labs 最好被视为一家具有全球影响力、强大产品特性和正在展开的美国增长催化剂的专业医疗技术公司。
